Shawn Seong
Chief Executive Officer Shaperon
Seminars
Wednesday 9th December 2026
Advancing GPCR19 Positive Allosteric Modulation: Phase I Data From NuCerin, a First-in-Class Therapy for Alzheimer’s Disease
12:00 pm
- Unravelling the mechanism of action of GPCR19 agonism
- Demonstrating simultaneous targeting of Aβ and neuroinflammation
- Reviewing results and key takeaways from the Phase I trial of NuCerin in South Korea
